CME Group Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CME Group Inc. on June 16, 2026, regarding a significant leadership transition. The report details the Board of Directors' approval of a plan for Terrence A. Duffy to step down as Chief Executive Officer (CEO) and be succeeded by Lynne C. Fitzpatrick.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and governance changes.
Material Changes
The primary material change is the announced succession plan for the CEO role:
- Terrence A. Duffy: Will transition from Chairman and CEO to Executive Chairman. He will serve as CEO until the "Transition Date" (the later of March 1, 2027, or the filing of the 2026 Form 10-K) and then serve as Executive Chairman through December 31, 2027.
- Lynne C. Fitzpatrick: Currently President and CFO, will succeed Mr. Duffy as CEO on the Transition Date. She will also be appointed to the Board and its Executive Committee.
- CFO Search: The Company will initiate a search for a successor to Ms. Fitzpatrick as Chief Financial Officer.
Compensation and Agreements
Terrence A. Duffy Transition Agreement:
- Base salary, bonus opportunity, and benefits generally remain the same as his prior agreement.
- Long-term incentives will be granted in fully vested shares in September 2027.
- Outstanding performance-based equity awards (excluding the 2026 period) will vest at the target level upon the Transition Date, subject to a release of claims.
- 2027 annual bonus will not require employment after year-end, subject to a release of claims.
Lynne C. Fitzpatrick Employment Agreement:
- Base Salary: $1.2 million annually.
- Bonus Opportunity: 200% of annual base salary.
- Long-Term Incentive: 700% of annual base salary.
- Severance: In the event of termination without cause or resignation with good reason, she is eligible for a lump sum equal to two times her annual base salary, a pro-rated bonus, accelerated vesting of 75% of unvested restricted shares, and 18 months of healthcare coverage.
- Covenants: Subject to a 12-month non-competition and non-solicitation covenant post-employment.
Investor Verification Checklist
- Verify the exact "Transition Date" once the 2026 Form 10-K is filed to confirm the effective date of the CEO change.
- Review the full text of the Transition and Executive Chairman Agreement (Exhibit 10.1) for specific restrictive covenants and performance metrics.
- Review the full text of the Employment Agreement (Exhibit 10.2) to understand the specific definitions of "good reason" and "termination without cause."
- Monitor future announcements regarding the selection of the new Chief Financial Officer.